Financial Snapshot

Revenue
$187.2M
TTM
Gross Margin
69.65%
TTM
Net Earnings
$6.872M
TTM
Current Assets
Q2 2024
Current Liabilities
Q2 2024
Current Ratio
133.5%
Q2 2024
Total Assets
Q2 2024
Total Liabilities
Q2 2024
Book Value
-$141.7M
Q2 2024
Cash
Q2 2024
P/E
46.23
Sep 13, 2024 EST
Free Cash Flow
$19.40M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019
Revenue $185.4M $165.0M $0.00 $0.00 $110.0M
YoY Change 12.37% -100.0%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019
Revenue $185.4M $165.0M $0.00 $0.00 $110.0M
Cost Of Revenue $57.88M $54.58M $48.82M $44.93M $43.60M
Gross Profit $127.5M $110.4M $90.58M $71.64M $66.40M
Gross Profit Margin 68.78% 66.92% 60.36%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019
Selling, General & Admin $98.83M $165.5M $200.0K $0.00 $42.10M
YoY Change -40.29% 82651.0% -100.0%
% of Gross Profit 77.52% 149.94% 0.22% 0.0% 63.4%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $2.994M $2.199M $1.400M $1.138M $830.0K
YoY Change 36.15% 57.07% 23.02% 37.11%
% of Gross Profit 2.35% 1.99% 1.55% 1.59% 1.25%
Operating Expenses $98.83M $165.5M $3.322M $0.00 $42.80M
YoY Change -40.29% 4882.46% -100.0%
Operating Profit $28.66M -$60.72M $34.56M $71.64M $23.60M
YoY Change -147.19% -275.7% -51.76% 203.56%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019
Interest Expense -$6.363M -$5.091M $18.91M -$2.425M -$2.100M
YoY Change 24.99% -126.92% -879.72% 15.48%
% of Operating Profit -22.2% 54.71% -3.39% -8.9%
Other Income/Expense, Net -$28.78M $62.43M -$4.474M -$5.000K -$100.0K
YoY Change -146.1% -1495.59% 89373.0% -95.0%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019
Pretax Income -$123.0K $1.712M $11.11M $0.00 $21.40M
YoY Change -107.18% -84.59% -100.0%
Income Tax $2.682M $388.0K $286.0K $189.0K $100.0K
% Of Pretax Income 22.66% 2.57% 0.47%
Net Earnings $3.316M -$969.0K $11.11M $0.00 $21.30M
YoY Change -442.21% -108.72% -100.0%
Net Earnings / Revenue 1.79% -0.59% 19.36%
Basic Earnings Per Share $0.13 -$0.12
Diluted Earnings Per Share $0.13 -$0.12 $280.0K $0.00 $2.55

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019
Cash & Short-Term Investments $89.00M $79.23M $130.4K $1.590K
YoY Change 12.33% 60678.61% 8098.74%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $9.225M $3.816M $321.0K $1.570M
YoY Change 141.75% 1088.93% -79.56%
Inventory $17.31M $11.18M $9.615M $4.324M
Prepaid Expenses
Receivables $6.809M $6.948M $5.231M $4.720M
Other Receivables $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $122.3M $101.2M $451.6K $1.590K
YoY Change 20.92% 22303.35% 28303.77%
Property, Plant & Equipment $3.095M $3.556M $2.691M $2.165M
YoY Change -12.96% 32.14% 24.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $317.6M
YoY Change
Other Assets $24.88M $1.838M $0.00 $145.9K
YoY Change 1253.86% -100.0%
Total Long-Term Assets $32.95M $10.47M $317.6M $145.9K
YoY Change 214.82% -96.7% 217555.95%
Total Assets $155.3M $111.6M $318.0M $147.5K
YoY Change
Accounts Payable $4.155M $4.112M $281.3K $2.445M
YoY Change 1.05% 1361.78% -88.49%
Accrued Expenses $8.808M $6.439M $1.830M $2.221M
YoY Change 36.79% 251.86% -17.6%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $122.5K
YoY Change -100.0%
Long-Term Debt Due $6.250M $6.250M $5.000M $5.000M
YoY Change 0.0% 25.0% 0.0%
Total Short-Term Liabilities $22.22M $18.77M $2.272M $122.5K
YoY Change 18.38% 725.9% 1754.84%
Long-Term Debt $106.6M $112.1M $0.00 $0.00
YoY Change -4.87%
Other Long-Term Liabilities $63.00M $39.07M $20.89M $1.211M
YoY Change 61.25% 87.0% 1625.12%
Total Long-Term Liabilities $169.6M $151.2M $20.89M $0.00
YoY Change 12.22% 623.53%
Total Liabilities $184.7M $156.1M $23.16M $122.5K
YoY Change 18.31% 573.93% 18808.85%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019
Basic Shares Outstanding 25.71M 8.059M
Diluted Shares Outstanding 25.71M 8.059M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $317.72 Million

About Biote Corp

biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. The company is headquartered in Irving, Texas and currently employs 194 full-time employees. The company went IPO on 2021-03-02. The firm provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. The company also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.

Industry: Medicinal Chemicals & Botanical Products Peers: CymaBay Therapeutics, Inc. EyePoint Pharmaceuticals Inc Oramed Pharmaceuticals Inc Johnson & Johnson Marinus Pharmaceuticals Inc OptiNose Inc Provention Bio, Inc.